{
    "clinical_study": {
        "@rank": "153225", 
        "arm_group": [
            {
                "arm_group_label": "paclitaxel liposome injection weekly", 
                "arm_group_type": "Experimental", 
                "description": "paclitaxel liposome injection 100mg/m2  administered by intravenous on day1 and  day8 of a  21-day cycle for 4-6 cycles or till progression or intolerable"
            }, 
            {
                "arm_group_label": "paclitaxel liposome injection every 3 weeks", 
                "arm_group_type": "Experimental", 
                "description": "paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a  21-day cycle for 4-6 cycles or till progression or intolerable"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a open-label Phase II study in  patients with metastatic breast cancer to evaluate\n      the antitumor activity and safety of weekly dose-dense paclitaxel liposome injection\n      compared to 3-weekly regimen."
        }, 
        "brief_title": "Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female or Male >18 years of age and < 70years of age, If female of childbearing\n             potential, pregnancy test is negative before first dose of study drug and agree to\n             use an acceptable method of birth control to avoid pregnancy for the duration of the\n             study\n\n          -  Stage IV disease\n\n          -  Measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n\n          -  Patients must not be a candidate for Herceptin therapy\n\n          -  Suitable for the treatment with paclitaxel as single agent regimen (prior\n             chemotherapy for metastatic disease was allowed. If a taxane was part of the adjuvant\n             regimen, at least one year should have transpired since completion of taxane regimen\n             and if Her2+ patient, Herceptin therapy will be allowed.\n\n          -  Patient has the following values at Baseline: Absolute neutrophil count \u2265 1.5 x\n             10^9cells/L; platelets \u2265 100 x 10^9 cells/L; hemoglobin \u2265 10 g/dL. Aspartate\n             transaminase (AST or SGOT), alanine aminotransferase (ALT or SGPT) \u2264 2.5x upper limit\n             of normal range (ULN); total bilirubin \u2264 1.5ULN; creatinine \u2264 1.5 mg/dL.\n\n          -  Informed consent has been obtained.\n\n        Exclusion Criteria:\n\n          -  Parenchymal brain metastases.\n\n          -  History of other malignancy within the last 3 years\n\n          -  New York Heart Association (NYHA) Grade 2 or greater congestive heart failure,history\n             of myocardial infarction or unstable angina or new occured angina  within 6 months\n             prior to study enrollment.\n\n          -  Concurrent other anticancer therapy.\n\n          -  History of serious organic disorders (including active infection or Cardiovascular\n             disease), serious hepatic disease, serious blood coagulation diseases, cachexia\n\n          -  Sensory neuropathy of > Grade 1 at baseline.\n\n          -  Patients with prior hypersensitivity to paclitaxel\n\n          -  Pregnant or nursing women\n\n          -  enrolled in a different clinical study\n\n          -  No psychiatric illness and other situations that would limit compliance of study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02142790", 
            "org_study_id": "LY-TM-LPS-2014-02"
        }, 
        "intervention": {
            "arm_group_label": [
                "paclitaxel liposome injection weekly", 
                "paclitaxel liposome injection every 3 weeks"
            ], 
            "intervention_name": "paclitaxel liposome injection", 
            "intervention_type": "Drug", 
            "other_name": "LIPUSU"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2014", 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "oyqc1969@126.com", 
            "last_name": "Quchang Ouyang, MD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142790"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Clinical Benefit Rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nanjing Luye Sike Pharmaceutical Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}